{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-037382","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.175338+00:00","generated_at":"2026-06-21T22:59:59.422385+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Trevi Therapeutics reports Q3 2022 net loss of $8.3M; cash at $126M","bullets":["Net loss of $8.3M in Q3 2022 vs. $7.3M in Q3 2021; R&D expenses rose to $5.8M.","Cash, cash equivalents, and investments totaled $126M as of Sept 30, 2022.","Phase 2 CANAL trial for chronic cough in IPF met primary endpoint with 75.1% reduction in cough frequency (placebo-adjusted 52.5%, p<0.0001).","Phase 2b/3 PRISM trial for prurigo nodularis open-label extension ongoing; end-of-phase 2 FDA meeting planned Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-037382","json":"https://secwatch.observer/filing/0001564590-22-037382.json","markdown":"https://secwatch.observer/filing/0001564590-22-037382.md","text":"https://secwatch.observer/filing/0001564590-22-037382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022037382/0001564590-22-037382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022037382/trvi-8k_20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:59:59.422385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb5db4572440b12dbf8f8388311f3b70e912371a","claim":"Trevi Therapeutics, Inc. reported quarter ended September 30, 2022 results: net income net loss of $8.3 million.","evidence_excerpt":"For the third quarter of 2022, the Company reported a net loss of $8.3 million, compared to a net loss of $7.3 million in the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022037382/0001564590-22-037382-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Net income","value":"net loss of $8.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}